15/03/2023 – AB Science will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform Download PDF Post navigationPreviousPrevious post:AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)NextNext post:AB Science webcast – Microtubule Destabilizer Agents (MDA) platformRelated PostsAB Science webcast – Microtubule Destabilizer Agents (MDA) platformMarch 16, 2023AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)March 13, 2023Publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer’s Research & TherapyFebruary 28, 2023AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment BankJanuary 31, 2023
AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)March 13, 2023
Publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer’s Research & TherapyFebruary 28, 2023
AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment BankJanuary 31, 2023
